Table 2.

Comparative effects of PCSK9 inhibitors on MACE components

Outcome	Evolocumab vs. Placebo (OR, 95% CI)	Alirocumab vs. Placebo (OR, 95% CI)	p for Indirect Comparison
All-cause mortality	0.85 (0.72–1.01)	0.82 (0.69–0.97)	0.62
Cardiovascular mortality	0.88 (0.72–1.08)	0.80 (0.68–0.94)	0.41
Non-fatal myocardial infarction	0.76 (0.62–0.92)	0.83 (0.70–0.98)	0.55
Hospitalization for UA	0.84 (0.68–1.04)	0.84 (0.71–0.98)	0.99
Coronary revascularization	0.72 (0.59–0.89)	0.79 (0.66–0.95)	0.48